On March 3, 2025, Neuralink filed trademark applications for several groundbreaking terms, including "Telepathy" (serial number 99063908) and "Telekinesis"123. These filings were made on an "intent-to-use" basis, indicating the company's active development of products under these names2. The "Telepathy" trademark is described as "an implantable brain to computer interface for facilitating communication and control of software and hardware"1. Additionally, Neuralink applied for other futuristic trademarks such as "Blindsight," suggesting technology aimed at restoring vision to those with sight loss45. These applications represent a significant step towards commercializing Neuralink's brain-computer interface technology, potentially expanding beyond medical applications into consumer products64.

The "Telepathy" trademark application describes a revolutionary implantable brain-computer interface designed to facilitate communication and control of software and hardware through thought alone12. This technology aligns with Elon Musk's vision for Neuralink's first product, which aims to enable individuals with paralysis to control computers or phones using only their minds3. Currently, Neuralink's technology involves a brain implant that collects neural signals and software that translates these signals into cursor movements on a computer screen4. The company's ambitions extend beyond medical applications, potentially enabling telepathic communication not just with electronic devices but possibly between humans with Neuralink implants25.

Neuralink's trademark application for "Telekinesis" hints at ambitious plans to develop technology that could allow users to control physical objects using only their thoughts. This concept, while seemingly straight out of science fiction, aligns with the company's broader vision of expanding human capabilities through brain-computer interfaces. The potential applications of such technology are vast, ranging from assistive devices for individuals with mobility impairments to revolutionary advancements in industrial automation and robotics12.

While specific details about Neuralink's "Telekinesis" technology remain undisclosed, it likely builds upon the company's existing brain-computer interface system. This system, which includes the "Link" implant and the "N1" electrode array, could potentially be adapted to interpret neural signals associated with intended movements and translate them into commands for external devices32. As Neuralink continues to refine its technology, the prospect of mind-controlled objects moves closer to reality, promising to reshape how humans interact with their physical environment.

As of February 2025, three individuals with paralysis have received experimental Neuralink implants as part of an early feasibility study, with the first recipient, Noland Arbaugh, undergoing brain surgery in January 20241. These trials mark a significant milestone in Neuralink's journey towards realizing its ambitious vision. The company's broader aspirations extend beyond assisting those with paralysis, as evidenced by their trademark filing for "Blindsight," which suggests technology aimed at restoring vision to those with sight loss23. This multifaceted approach underscores Neuralink's commitment to addressing various neurological challenges and expanding the potential applications of their brain-computer interface technology.